Date: January 8, 2025
The Canadian Drug Agency (CDA) has launched a consultation to gather feedback on proposed improvements to its drug reimbursement review processes. These enhancements aim to increase transparency, efficiency, and accelerate patient access to effective treatments.
Read moreKey Topics of the Consultation:
Stakeholders are encouraged to provide feedback by February 6, 2025. For more information and to participate in the consultation, visit:
Learn moreDate: December 19, 2024
NICE has launched a public consultation on changes to its Highly Specialised Technologies routing criteria, aimed at clarifying decision-making for rare conditions.
Read moreDetails of the consultation are available on NICE's official website. Stakeholders are encouraged to provide feedback.
Learn moreDate: December 10, 2024
NICE has approved vamorolone, a treatment for Duchenne muscular dystrophy, after a new price agreement. The therapy benefits about 1,700 people in England.
Read moreThe new price deal ensures the availability of this critical treatment for patients in need. For additional details, visit:
Learn moreDate: November 28, 2024
Canada's Drug Agency has launched a public consultation on its first methods guide for health technology assessments. Open until January 28, 2025, the guide aims to improve transparency in drug reimbursement reviews.
Read moreThe guide is designed to provide clarity on health technology assessments. Stakeholders are encouraged to participate in the consultation. For more details:
Learn moreDate: November 14, 2024
HAS renewed memberships for its Transparency Commission and National Evaluation Commission for Medical Devices, ensuring balanced expertise.
Read moreThe appointments aim to ensure balanced expertise and informed decision-making. For further information, visit:
Learn more